Tymlos (abaloparatide) and Forteo (teriparatide) are the two daily bone-building injections approved for osteoporosis in the United States, and both are sold as pre-filled pens. That makes the price question easier than it is for most drugs: one pen is a fixed number of days, and both labels limit treatment to about two years in a lifetime, so the whole course is a finite number of pens.
There is no retail cash price we could read on 16 November 2026. GoodRx redirected all three product pages to a block page, SingleCare and Drugs.com returned HTTP 403, and Lilly's price-information site refused the automated read. Per this site's method, a refused page is excluded and never quoted from a search snippet. What follows comes from three government datasets and the two manufacturers' own pages, each with a date. How the two drugs compare on indications, bone density and fractures is on our Tymlos vs Forteo comparison; this page is only the money.
What is in a pen
| Product | Pen contents | Doses per pen | Days per pen | Approved by FDA |
|---|---|---|---|---|
| Tymlos (Radius Health) | 3,120 mcg abaloparatide in 1.56 mL | 30 × 80 mcg | 30 | 28 April 2017 (NDA 208743) |
| Forteo (Eli Lilly) | 560 mcg teriparatide in 2.24 mL | 28 × 20 mcg | 28 | 26 November 2002 (NDA 021318) |
| Bonsity (Alvogen) | 560 mcg teriparatide in 2.24 mL | 28 × 20 mcg | 28 | 4 October 2019 (NDA 211939) |
| Teriparatide, Teva / Apotex | 560 mcg teriparatide in 2.24 mL | 28 × 20 mcg | 28 | 16 November 2023 (ANDAs 208569, 211097) |
| Teriparatide, Amphastar | 560 mcg teriparatide in 2.24 mL | 28 × 20 mcg | 28 | 12 December 2025 (ANDA 213641) |
Pen contents and dose counts are from each product's current label (Forteo label effective 3 August 2026, Tymlos 11 August 2026). Approval dates are the original approvals in Drugs@FDA. Lilly's earlier Forteo pen held 750 mcg in 3 mL and is listed as discontinued.
The 28-day versus 30-day difference matters when prices are compared: a "monthly" cost for teriparatide is slightly more than one pen.
The acquisition cost per pen
NADAC is Medicaid's weekly survey of what retail pharmacies actually paid wholesalers. It prices injectables per millilitre, so the figures below are the per-mL rate multiplied by the pen's volume.
| Product | NADAC per mL | Per pen | Per day | 30 days | As of |
|---|---|---|---|---|---|
| Forteo | $1,840.77 | $4,123 | $147.26 | $4,418 | file of 11 Nov 2026 (rate effective 21 Oct 2026) |
| Tymlos | $1,745.14 | $2,722 | $90.75 | $2,722 | last listed 5 Nov 2025 |
| Generic teriparatide | $473.07 | $1,060 | $37.85 | $1,135 | file of 11 Nov 2026 (rate effective 21 Oct 2026) |
Per-pen, per-day and 30-day figures are our arithmetic. NADAC sets a single rate for all generic versions of the same product, so the teriparatide row covers the six labellers it lists (NDCs beginning 00093, 47781, 60505, 66993, 00548 and 68001).
Tymlos has left the survey. Its last NADAC entry is in the file of 5 November 2025; the 2026 file contains no row for Tymlos or abaloparatide. NADAC does not publish a reason for an individual product leaving. The 2025 figure is therefore the most recent public acquisition cost for Tymlos, and it is a year old.
The generic price that keeps falling
The NADAC rate for generic teriparatide, read from the 2025 and 2026 files:
| Rate first seen | Per mL | Per pen |
|---|---|---|
| 2 April 2025 | $846.07 | $1,895 |
| 22 October 2025 | $670.53 | $1,502 |
| 7 January 2026 | $673.25 | $1,508 |
| 18 February 2026 | $624.89 | $1,400 |
| 22 April 2026 | $540.38 | $1,210 |
| 19 August 2026 | $494.81 | $1,108 |
| 11 November 2026 | $473.07 | $1,060 |
That is a fall of 44% since April 2025 and 30% since January 2026, in a year when FDA approved a further generic (Amphastar, December 2025) and a sixth labeller appeared in the survey (NDC 68001, from April 2026). Over the same 2026 files, Forteo's rate stayed between $1,840.34 and $1,848.10 per mL, a movement of under 1%. The gap between the brand and the generic has widened to about 3.9 to 1 for the same 560 mcg pen.
Medicare: what it spent in 2024
CMS's Part D Spending by Drug dataset (2024, before manufacturer rebates):
| Product | Total spending | Claims | People | Average per mL | Per pen at that rate |
|---|---|---|---|---|---|
| Tymlos | $257.6 million | 88,564 | 16,530 | $1,690.96 | $2,638 |
| Forteo | $266.4 million | 67,653 | 11,433 | $1,571.07 | $3,519 |
| Teriparatide (generic name) | $212.6 million | 81,093 | 15,831 | $962.44 | $2,156 |
Per-pen figures are our multiplication of CMS's per-unit average by the pen volume, assuming the unit is the millilitre, as it is in NADAC; CMS does not state the unit per drug in this file.
Three things in the series stand out. Tymlos spending almost doubled between 2020 and 2024 (+94%, from $132.8 million), as the number of people using it rose from 11,704 to 16,530. Forteo's spending fell 42% over the same years, from $457.3 million. And in 2024, teriparatide sold under its generic name already accounted for 55% of all teriparatide claims in Part D. CMS lists four manufacturers in that row for 2024: Alvogen, Prasco, Teva and Apotex. The Part D averages are higher than the 2026 generic NADAC because they are 2024 figures and include pharmacy payment, not only acquisition cost.
The two-year course
Both labels set a lifetime limit, worded differently. The Tymlos label: use "for more than 2 years during a patient's lifetime is not recommended." The Forteo label, and every generic teriparatide label we read, states that use beyond 2 years "should only be considered if a patient remains at or has returned to having a high risk for fracture."
At the acquisition costs above, a 730-day course comes to:
| Product | Pens for 730 days | Course at NADAC |
|---|---|---|
| Forteo | 26.1 | about $107,500 |
| Tymlos | 24.3 | about $66,200 (2025 rate) |
| Generic teriparatide | 26.1 | about $27,600 |
These are our arithmetic, before any pharmacy margin, insurer rebate or copay. They are not what a patient pays. They do show the scale of the purchase a prescriber and insurer are weighing, and that the gap between the three options is tens of thousands of dollars over a course.
Medicare negotiation
Neither drug has a negotiated Medicare price. Teriparatide is not eligible in practice: CMS removes a drug from the programme once a generic is approved and marketed, and generic teriparatide has been on the market since at least 2020 in Part D data.
Tymlos is the one to watch. On CMS's fact sheet of the top 50 negotiation-eligible drugs for 2028, Tymlos is number 35, with $359.1 million in combined Part B and Part D spending from November 2024 to October 2025. Only the top 15 were selected for that cycle, and Tymlos is not in CMS's selected-drug data file of 2 November 2026. Whether it is selected in a later cycle is not known.
What the manufacturers publish
- Tymlos. tymlos.com, read on 16 November 2026, states that eligible commercially insured patients "may pay as little as $0 a month", subject to an annual cap, and that the offer "is not valid for patients using Medicare, Medicaid, or other government programs." The same page states Tymlos is covered by 92% of commercial plans, and describes a Radius Assist patient assistance programme that ships at least three months per shipment, up to a total of 24 months of therapy, to patients it accepts. No list price is published on the site.
- Forteo. Lilly's Forteo site and its price-information site both refused the automated read on 16 November 2026. Nothing from them is quoted here.
What these figures do not tell anyone
- A cash price at a given pharmacy. NADAC is an average acquisition cost; pharmacies add a dispensing margin. None of the cash-price sites we tried could be read.
- Net prices. Manufacturer rebates to insurers are confidential; the Medicare spending figures are gross.
- Which drug is the right one. The two drugs differ in dose, pen and trial record, and the choice between them, or whether either is indicated, is a question for the prescriber. Coverage and copay questions go to the insurer.
Where these drugs sit among the other approved peptide medicines is on our FDA-approved peptides census. Their labelled side effects are set out on our Tymlos side effects and Forteo side effects pages, and prices across the peptide market are surveyed on how much do peptides cost.
Sources
- Medicaid NADAC 2025 and 2026 datasets, data.medicaid.gov API (datasets f38d0706… and fbb83258…), product descriptions containing TYMLOS, FORTEO 560 and TERIPARATIDE 560; latest file as of 11 November 2026; read 16 November 2026.
- CMS, Medicare Part D Spending by Drug, data.cms.gov API, Tymlos, Forteo and Teriparatide rows for 2020–2024, read 16 November 2026.
- Drugs@FDA via openFDA, applications for abaloparatide and teriparatide (NDA 208743, NDA 021318, NDA 211939, ANDAs 208569, 211097, 213641), data updated 13 November 2026; openFDA drug labels for Tymlos (effective 11 August 2026), Forteo (3 August 2026) and the teriparatide labels of Alvogen, Teva, Apotex, Amphastar, Prasco and BluePoint; read 16 November 2026.
- CMS, Fact Sheet: Top 50 Negotiation-Eligible Drugs for Initial Price Applicability Year 2028 (PDF), and the Selected Drug List and Maximum Fair Price data file of 2 November 2026, read 16 November 2026.
- tymlos.com, access and savings page with savings-card terms, rendered 16 November 2026.
- Refused (excluded): goodrx.com/tymlos, /forteo and /teriparatide (redirected to a block page), singlecare.com and drugs.com price guides (HTTP 403), pricinginfo.lilly.com and forteo.lilly.com (HTTP 403), all 16 November 2026.
